{
  "url": "https://struct.news/briefs/praxis-has-three-times-the-cash-and-a-much-bigger-clinical-burn",
  "title": "Praxis has three times the cash, and a much bigger clinical burn",
  "summary": "$163.7 million left Praxis through operations in six months, up from $107.7 million a year earlier.",
  "published_at": "2026-08-06T12:38:36.056827+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Praxis Precision Medicines, Inc",
    "ticker": "PRAX",
    "cik": "1689548",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-06",
    "accession": "0001689548-26-000083",
    "url": "https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-04",
    "url": "https://www.sec.gov/Archives/edgar/data/1689548/000168954825000092/prax-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 0,
      "display": "$0.00",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001689548-26-000083",
        "filing_date": "2026-08-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": -100,
      "display": "-100.0%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001689548-26-000083",
        "filing_date": "2026-08-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Diluted share change",
      "value": 25.676745932298097,
      "display": "+25.7%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001689548-26-000083",
        "filing_date": "2026-08-06"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "Solidus expense rose $9.7 million, including a $5.0 million Ionis milestone and EMBRAVE3 pivotal-trial spending.",
      "importance": "medium",
      "evidence": "$9.7 million increase in expense related to our Solidus™ platform, driven primarily by a $5.0 million milestone payment due to Ionis Pharmaceuticals Inc., or Ionis, upon completion of our EMBRAVE Part A study, as well as spend for our EMBRAVE3 pivotal clinical trial",
      "source_date": "2026-08-06"
    }
  ],
  "related_tickers": [
    "PRAX"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}